ER-Negative Isolated Locoregional Recurrence Benefits From Chemotherapy

Catherine Beriloff

Click Here To View Other Testimonials

Amazon Smile

Please use the link below to order from Amazon. 5% of total sales will go to Rocking the Road for a Cure to help the org continue free breast cancer wellness programs and support services.

This app does not expire so keep us in mind when shopping; even during the holidays.

Please share with others.
Thank you for your support!

ER-Negative Isolated Locoregional Recurrence Benefits From Chemotherapy

Posted OnMarch 7, 2018 Rocking The Road For A Cure 0

[ Original Article: Modern Medicine Network, Author: Dave Levitan, Feb 21 2018 ]

A final analysis of the randomized CALOR trial found that patients with estrogen receptor (ER)-negative isolated locoregional recurrence (ILRR) after unilateral breast cancer derive significant benefit from chemotherapy, while those with ER-positive disease do not.
READ MORE